64 results about "Ambroxol" patented technology

The invention relates to an ambroxol hydrochloride oral solution which is prepared from the following raw and auxiliary materials in parts by weight: 0.3-0.6 part of ambroxol hydrochloride; 0.04 to 0.06 part by weight of benzoic acid; 0.3 to 0.6 part by weight of hydroxyethyl cellulose; 0.08 to 0.2 part by weight of sucralose; 0.15 to 0.4 part by weight of essence; and the balance of purified water. The preparation method comprises the following steps: S1, adding a base solution; S2, adding ingredients; and S3, filtering. The preparation method comprises the following steps: S1, hydroxyethyl cellulose pretreatment; S2, mixing; S3, seasoning; and S4, packaging. The invention provides an ambroxol hydrochloride oral solution and a preparation method thereof. The ambroxol hydrochloride oral solution is good in taste, high in stability and high in patient compliance. And the production process is simple, stable, controllable and easy to industrialize.

The invention discloses an ambroxol hydrochloride liquid filling detection method and system, and relates to the technical field of filling detection.The method comprises the steps that after ambroxol hydrochloride liquid filling is completed, a filling bottle is clamped to the position in front of a black background plate through a mechanical arm, a light source is controlled to collect a first to-be-detected image based on a first preset illumination parameter, and the first to-be-detected image is obtained; clamping the filling bottle to the front of the white background plate through a mechanical arm, and controlling the light source to collect a second to-be-detected image based on a second preset illumination parameter; processing the first preset illumination parameter to obtain a first coded image; processing the second preset illumination parameter to obtain a second coded image; and performing deviation analysis, and when the identifier is a difference identifier, generating an abnormal identifier, and sending the abnormal identifier to the user side. The technical problem that in the prior art, after ambroxol hydrochloride liquid is filled, the abnormal filling condition is difficult to accurately detect is solved, and the technical effects that the abnormal filling condition is effectively detected, and the product filling quality is guaranteed are achieved.

Described herein, inter alia, are compositions comprising and methods of making and using endothelial cells (ECs) comprising one or more mitophagy-inducing agents (e.g., rapamycin, SKF-96365, lithium, carbamazepine, latrepirdine, spermidine, resveratrol, sodium valproate, trehalose, kaempferol, metformin, AICAR, nilotinib, ambroxol, curcumin, and VL-004). Also described herein, inter alia, are methods vascular cell therapy, promoting blood vessel formation, and increasing vascular development, angiogenesis, and cell junction via administration of a population of ECs comprising a mitophagy-inducing agent (MIA-ECs).

The present invention relates to an ambroxol-ibuprofen cocrystal dry powder inhaler, a preparation method and application thereof, and belongs to the professional field of pharmaceutical preparations. The dry powder inhaler is mainly composed of ambroxol, ibuprofen and lactose, the molar ratio of ambroxol to ibuprofen is 1:1, and the mass ratio of lactose to ambroxol-ibuprofen cocrystal is 5-35%. The results of the rat lung tissue distribution experiment showed that the administration method of dry powder inhalation can significantly enhance the drug delivery efficiency in the lungs and greatly prolong the drug retention time in the lungs compared with the traditional intravenous administration. Pharmacodynamic experiments further revealed that the ambroxol-ibuprofen cocrystal dry powder inhaler can effectively inhibit the active expression of inflammatory factors in model animals, and reduce the accumulation of hydroxyproline (HYP) in lung tissue and serum, improve anti-fibrosis and anti-inflammatory capabilities, improve oxidative stress capabilities, thereby helping to delay the pathological process of pulmonary fibrosis, showing great development potential as an anti-pulmonary fibrosis drug.

The invention relates to an ambroxol and ibuprofen eutectic dry powder inhaler as well as a preparation method and application thereof, and belongs to the professional field of pharmaceutical preparations. The dry powder inhalant is mainly composed of ambroxol, ibuprofen and lactose, the molar ratio of ambroxol to ibuprofen is 1: 1, and the mass ratio of lactose to ambroxol and ibuprofen eutectic is 5-35%. A rat lung tissue distribution experiment result shows that compared with traditional intravenous administration, the delivery efficiency of the medicine in the lung can be remarkably enhanced by adopting a dry powder inhalation administration mode, and the retention time of the medicine in the lung is greatly prolonged. The pharmacodynamic experiment further reveals that the ambroxol and ibuprofen eutectic dry powder inhalant can effectively inhibit the active expression of inflammatory factors in a model animal body, reduce the accumulation of hydroxyproline (HYP) in lung tissues and serum, improve the anti-fibrosis and anti-inflammatory ability and improve the oxidative stress ability, so that the pathological process of pulmonary fibrosis is delayed, and the inhalant can be used for treating pulmonary fibrosis. The compound shows huge development potential as an anti-pulmonary fibrosis drug.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an ambroxol hydrochloride-containing oral liquid and application thereof, and the ambroxol hydrochloride oral liquid is composed of ambroxol hydrochloride, ligustrazine, meglumine, dextran 40, xylitol, carboxymethylcellulose, L-tryptophan, stevioside and purified water. The ligustrazine and the ambroxol hydrochloride play a synergistic effect, and the meglumine and the dextran 40 are combined for use, so that the stability of the ambroxol hydrochloride is improved. Accelerated experiments show that the ambroxol hydrochloride is stable in property and suitable for further industrial mass production.

The application provides an ambroxol oral dissolving film composition, a preparation method and application thereof. The ambroxol oral dissolving film composition comprises an active drug, a film forming material and a taste masking agent, and the active drug is 2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl) benzylamine and / or a pharmaceutically acceptable salt thereof, for example, ambroxol hydrochloride. The ambroxol oral dissolving film composition provided by the application has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without drinking water, and fast oral absorption speed. Moreover, the ambroxol oral dissolving film composition has the advantages of simple process, high drug loading, good drug content uniformity, and good market prospect.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a pharmaceutical composition containing ambroxol and application of the pharmaceutical composition to children asthma. The pharmaceutical composition containing ambroxol is prepared from the following components in parts by weight: 10 to 30 parts of ambroxol hydrochloride and 30 to 60 parts of fructus polygoni orientalis extract. The ambroxol hydrochloride and the fructus polygoni orientalis extract are combined to form the novel pharmaceutical composition, and animal experiments show that the pharmaceutical composition can remarkably reduce the airway sensitivity of rats and reduce the IL-4 and IgE levels in serum of the rats.

The invention discloses an ambroxol hydrochloride preparation composition and a preparation method thereof, the ambroxol hydrochloride preparation composition contains hydroxyethyl cellulose, and the weight-average molecular weight of the hydroxyethyl cellulose is selected from 900000 to 1100000. By improving the prescription raw materials and the prescription process, the production equipment requirement and cost are greatly reduced while the product quality is ensured, and the preparation method is very suitable for large-scale industrial production.

The invention discloses a production process of an ambroxol oral solution, and belongs to the technical field of chemical medicinal preparations, the production process comprises the following steps: adding an aqueous solution containing ambroxol hydrochloride, clenbuterol hydrochloride, sorbitol, propylene glycol, glycerol, hydroxyethyl cellulose, DL-tartaric acid and sodium benzoate into a reaction kettle, and uniformly stirring to obtain the ambroxol hydrochloride oral solution, the clenbuterol hydrochloride, the sorbitol, the propylene glycol, the glycerol, the hydroxyethyl cellulose, the DL-tartaric acid and the sodium benzoate; the preparation method comprises the following steps: preparing in a production system passivated by hydroxyethyl diamine tetraacetic acid trisodium salt, treating by a two-stage series hollow membrane contactor, and finally filling a glass bottle with a liquid medicine. According to the preparation method disclosed by the invention, on the basis of prescription adjustment without adding antioxidants such as sodium pyrosulfite and the like, the impurities of the medicine in the production and storage processes are obviously reduced, the product stability and the clinical medication safety are improved, and the preparation process is simple and stable to operate and suitable for industrial production.

The invention discloses an HPLC (High Performance Liquid Chromatography) detection method for sucralose, sorbitol and cane sugar in an ambroxol hydrochloride oral solution. The HPLC detection method comprises the following steps: a, preparing a reference substance solution; b, preparing a test solution; c, respectively sucking the reference solution and the test solution and injecting into an HPLC-ELSD (High Performance Liquid Chromatography-Evaporative Light Scattering Detector); chromatographic conditions are as follows: a chromatographic column: a C18 column is connected in series with an amino column; and the mobile phase is 65% acetonitrile aqueous solution. The method is rapid, efficient and high in sensitivity, sucralose, sorbitol and cane sugar in the ambroxol hydrochloride oral solution can be accurately quantified at the same time, a simple and accurate method is provided for detection of the ambroxol hydrochloride oral solution, the quality of the ambroxol hydrochloride oral solution is guaranteed, a scientific basis is provided for clinical application of the ambroxol hydrochloride oral solution, and the method is worthy of popularization and application. Good application prospects are realized.

The invention discloses a porous core-shell microsphere with thermosensitivity and acid responsiveness and a preparation method of the porous core-shell microsphere, and belongs to the technical field of biological medicines. The preparation method comprises the following steps: S1, carrying out a reaction on hyaluronic acid and 3, 3 '-dithiobis (propionyl hydrazide) to obtain hydrazide modified hyaluronic acid HA-TPH; s2, another part of hyaluronic acid is taken and modified with sodium periodate, and oxidized modified hyaluronic acid HA-CHO is obtained; s3, dissolving HA-TPH in water, and adding beclomethasone dipropionate to obtain a solution A; dissolving HA-CHO in water, and adding beclomethasone dipropionate to obtain a solution B; s4, the solution A and the solution B are mixed and then dropwise added into vegetable oil, and spherical gel particles are prepared through an emulsification method; s5, dissolving the shell layer material in dichloromethane, and then adding ambroxol hydrochloride and the gel particles to form an electronic injection suspension; and S6, preparing the porous core-shell microspheres by adopting a uniaxial electronic injection method. The microspheres prepared by the invention have both thermosensitivity and acid responsiveness, and the problems of inaccurate release, low utilization rate and the like of the traditional dosage form are solved.

The invention relates to solid compositions and methods of manufacture. The present invention addresses the problem of providing a solid composition which contains at least one component selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof, and another component, and in which changes in properties are suppressed. [Solution] A solid composition containing the following components: (A) at least one substance selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof; (B) fructose; and (C) one or more components selected from the group consisting of: (C-1) vitamin B1 and vitamin C; (C-2) Chinese herbaceous peony, liquorice and valerian; (C-3) bromhexine, ambroxol, tepiperidine, salts thereof, and hydrates thereof; (C-4) clomastine, salts thereof, and hydrates thereof; and (C-5) dextromethorphan, salts thereof, and hydrates thereof.

The invention provides a method for determining the content of clenbuterol hydrochloride in an ambroxol oral solution, which comprises the following steps: respectively injecting a diluent, a reference solution and a test solution into a two-dimensional high performance liquid chromatograph, recording chromatograms, and calculating the content of clenbuterol hydrochloride by peak area according to an external standard method. The first-dimensional liquid chromatography conditions are as follows: a phosphoric acid buffer solution-methanol-acetonitrile is taken as a mobile phase A, methanol is taken as a mobile phase B, and gradient elution is carried out; the second-dimensional liquid chromatography conditions are as follows: phosphoric acid buffer solution-methanol-acetonitrile is taken as a mobile phase A, and switching is performed according to a specific program. The detection method disclosed by the invention is simple and convenient, the interference of a matrix in a sample can be well solved, the peak area response of a main component can be increased by about 5 times compared with that of a common high-performance liquid phase, and the detection limit is as low as 0.02 mu g / ml; the method is good in system applicability, good in specificity, good in repeatability, high in accuracy and good in solution stability, and can be used for quantitatively detecting the content of clenbuterol hydrochloride in the medicine.

The present application relates to the technical field of nucleic acid extraction and purification, and particularly relates to a DNA and RNA co-extraction reaction reagent and an extraction method, the reaction reagent comprising a nucleic acid protective agent RP, a sample lysis and binding liquid LB, a protein washing liquid WB1, a nucleic acid rinsing liquid WB2, and a nucleic acid elution liquid EB; the nucleic acid protective agent RP comprising DTT, mercaptoethanol, TCEP, and sodium hydroxide; the sample lysis and binding liquid LB comprising Tris-HCl, benzenesulfonic acid, sodium citrate, guanidine hydrochloride, guanidine isothiocyanate, guanidine thiocyanate, urea, triton X-100, SDS, potassium chloride, sodium chloride, bromhexine, N-acetylcysteine, ambroxol hydrochloride, isopropyl alcohol, and anhydrous ethanol; the protein washing liquid WB1 comprising Tris-HCl, benzenesulfonic acid, sodium citrate, guanidine hydrochloride, guanidine isothiocyanate, guanidine thiocyanate, urea, triton X-100, sodium chloride, isopropyl alcohol, and anhydrous ethanol; the nucleic acid rinsing liquid WB2 comprising Tris-HCl, sodium chloride, isopropyl alcohol, and anhydrous ethanol; and the nucleic acid elution liquid EB being nuclease-free water; the reagent can rapidly and fully enrich and purify DNA and RNA of a sample simultaneously.

The invention provides a method for detecting clenbuterol hydrochloride by removing hydroxyethyl cellulose in an ambroxol oral solution. According to the present invention, the high performance liquid chromatography is adopted, the HEC can form the precipitate capable of being centrifugally separated by using the acetonitrile-isopropanol mixed solvent, the interference source of the HEC is directly completely removed through the simple liquid-solid separation, the content of the clenbuterol hydrochloride is not affected, the viscosity of the test solution is equivalent to the viscosity of the mobile phase, and the detection result is accurate. According to the method, the chromatographic column is fundamentally prevented from being blocked and polluted, the service life of the chromatographic column is prolonged, a protection column is not needed, the cost is saved, the viscosity of a sample is reduced, the peak area of the clenbuterol hydrochloride is large, and the repeatability is obviously improved. The method is high in specificity, high in linearity, accuracy and precision and good in durability.

In certain embodiments, liquid formulations for oral administration are disclosed, comprising an amphiphilic material and ambroxol or a pharmaceutically acceptable salt thereof.

The invention provides an ambroxterol composition and a preparation process thereof, and particularly relates to the field of medicines. Each milliliter of the liquid preparation comprises 1-2mg of ambroxol hydrochloride, 0.5-1.5 [mu] g of clenbuterol hydrochloride, 10-20mg of sodium hydrogen sulfite, 1-4mg of hydroxyethyl cellulose and purified water. The toothpaste further comprises 243-247 mg of an amorphous sorbitol solution, 3-5 mg of pomegranate essence, 148-152 mg of glycerin, 1-3 mg of sodium benzoate and a proper amount of DL-tartaric acid. According to the preparation disclosed by the invention, the increase of an impurity B can be inhibited by adding sodium hydrogen sulfite, and the increase of an ambroxol impurity 14 and an unknown single impurity can be reduced by reducing the dosage of hydroxyethyl cellulose, so that the drug stability is improved.

The invention discloses a method for detecting N-nitroso ambroxol in a medicine through LC-MS / MS, and belongs to the technical field of medicine analysis. According to the method for detecting N-nitroso ambroxol in the medicine through LC-MS / MS, the medicine is an ambroxol-containing preparation or ambroxol and a salt bulk drug thereof, and liquid chromatography conditions comprise that octadecylsilane chemically bonded silica is used as a filler, 0.05-0.2% formic acid is used as a mobile phase A, and acetonitrile is used as a mobile phase B for gradient elution; the mass spectrum conditions comprise that a mass spectrum detector and an electrospray positive ion mode are adopted, multi-reaction detection is carried out, and m / z 377.9 to 279.2, m / z 377.9 to 114.3 and m / z 377.9 to 96.3 are selected as detection ion pairs. The method for detecting the ambroxol-containing preparation and the raw materials by adopting LC-MS / MS is high in sensitivity, good in accuracy and suitable for quality control of trace nitrosamine impurities in the preparation and the raw materials.

Formulations, are used for eye treatments, e.g., cross-linking treatments. For example, a therapeutic formulation includes a photosensitizer and delivery agent(s), wherein the delivery agent(s) include at least one of: anesthetic agent(s), analgesic agent(s), tonicity agent(s), or shear-thinning, or viscosity-increasing agent(s). In another example, a method includes applying preparatory formulation(s) to increase a permeability of a corneal epithelium, and applying therapeutic formulation(s) to the epithelium, where the preparatory formulation(s) include zinc metalloproteinase, copper metalloproteinase, papain, bromelain, actinidin, ficain, N-acetylcysteine, ambroxol, carbocisteine, and / or erdosteine. In yet another example, a method includes applying therapeutic formulation(s) to a corneal epithelium to deliver the therapeutic formulation(s) to a stroma, and applying enhancement formulation(s) to the epithelium in response to applying the therapeutic formulation(s), where: the enhancement formulation(s) remove the therapeutic formulation(s) from the epithelium; close tight junctions of the epithelium; promote oxidation for the therapeutic agent(s); and / or further deliver the therapeutic formulation(s) to the stroma.

1. The name of the design product: packaging box (ambroxol hydrochloride oral solution). 2. The use of the design product: for product packaging. 3. The design points of the design product: in the combination of shape and pattern. 4. The picture or photo that best indicates the design points: front view.

1. The name of the product of this design: packaging box (Ambroxol Hydrochloride Injection). 2. Purpose of this design product: used for medicine packaging boxes. 3. The design key point of this appearance design product lies in the combination of shape and pattern. 4. The picture or photo that best illustrates the key points of the design: main view. 5. The design for which protection is sought includes color.

The invention provides a polypeptide coupling medicine and application thereof. The polypeptide coupling medicine comprises antiviral polypeptide, connecting polypeptide, amino acid and ambroxol which are connected in sequence. The polypeptide coupling drug provided by the invention is obtained by coupling a coronavirus membrane fusion inhibitor and ambroxol, and is formed by coupling polypeptide serving as a targeting carrier and a load drug through a connexon via a covalent bond. Through polypeptide coupled drug activity evaluation and pharmacokinetic research, evaluation of activity changes of polypeptide and ambroxol and research on drug exposure and half-life periods of inhalants and injections, the polypeptide coupled drug retains antiviral activity of polypeptide and phlegm eliminating / respiratory tract regulating functions of ambroxol, the drug exposure is increased, and the half-life period is prolonged.

1. The name of the product of this design: packaging box (Ambroxol Hydrochloride Oral Solution). 2. Purpose of this design product: This design product is used for product packaging. 3. The design key point of this appearance design product lies in the combination of shape and pattern. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an oral instant film agent of ambroxol or hydrochloride thereof and a preparation method of the oral instant film agent. The oral instant film agent comprises the following components: an active component, a film forming material, a plasticizer and a taste masking agent, and the active component is ambroxol or hydrochloride thereof; the film-forming material comprises hydroxypropyl methylcellulose E5, hydroxypropyl methylcellulose E15 and xanthan gum, and the weight ratio of the film-forming material to the active component (calculated as ambroxol) is (2-5.5): 1. In order to mask the taste of the active components, the taste masking agent in the formula of the oral instant film is relatively high, and the good film-forming property and taste of the oral instant film are ensured by selecting and compounding three film-forming materials and using the pH regulator. The oral cavity instant film can be rapidly disintegrated and dissolved in the oral cavity, is good in taste and high in drug release speed, and can take effect rapidly.

The application provides an ambroxol oral dissolving film composition, a preparation method and application thereof. The ambroxol oral dissolving film composition comprises an active drug, a film forming material and a taste masking agent, and the active drug is 2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl) benzylamine and / or a pharmaceutically acceptable salt thereof, for example, ambroxol hydrochloride. The ambroxol oral dissolving film composition provided by the application has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without drinking water, and fast oral absorption speed. Moreover, the ambroxol oral dissolving film composition has the advantages of simple process, high drug loading, good drug content uniformity, and good market prospect.

This invention relates to an ambroxol oral solution. Specifically, this invention provides an ambroxol oral solution comprising ambroxol hydrochloride, clenbuterol hydrochloride, sucralose, mannitol, trehalose, hydroxyethyl cellulose, citric acid, sodium citrate, sodium bisulfite, glycine, glycerol, and water. The ambroxol oral solution of this invention effectively improves bitterness and its residue, has an excellent taste, and also exhibits excellent stability under light, high temperature, and high humidity, thus providing excellent storage and transportation stability and ensuring quality and safety.

The invention relates to a preparation method of ambroxol hydrochloride and an intermediate thereof, in particular to a preparation method of a structure shown in a formula II and a method for further preparing ambroxol hydrochloride. The ambroxol hydrochloride is obtained by taking o-aminobenzaldehyde as an initial raw material and sequentially carrying out three-step reaction of reductive amination, bromination and salification. The preparation method provided by the invention is a brand new technical route and is not reported in any literature and patent. According to the method, the yield of the product can be greatly improved, and the method is suitable for industrial production.

To provide treatment of glycogen storage disease (GSD).SOLUTION: The present invention relates to a kit of parts comprising (i) a pharmacological chaperone or a pharmaceutically acceptable salt thereof and (ii) a therapeutic acid alpha glucosidase (GAA) polypeptide or a nucleic acid molecule encoding a therapeutic GAA polypeptide, wherein the pharmacological chaperone is 1-deoxynojirimycin (DNJ) or a derivative thereof and Ambroxol (ABX) or a derivative thereof.SELECTED DRAWING: None

The present application provides a kind of antitussive and expectorant medicine, by adding flurbiprofen to traditional strong loquat, in addition to the anti-inflammatory effect of flurbiprofen, it can also significantly improve the antitussive and expectorant efficacy of traditional strong loquat; Patients do not need to take other expectorant drugs at the same time, such as ambroxol, etc., improve the compliance of cough and phlegm patients for drugs, and show obvious advantages in clinic.